BioTech Archives - Page 10 of 52

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.

German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders. The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.

This research project was launched in 2020 at the BioMed X Institute in Heidelberg and led by Dr. Ebru Ercan Herbst, now a professor at Reutlingen University, Germany. Her team has created both in vivo and in vitro platforms to study myelination of neurons and the development of oligodendrocytes – a subtype of glial cells – in the context of schizophrenia. Their novel in vitro platform for studying myelination was published last year in Cell Press – STAR Protocols (PMID: 36933222). Dr. Ercan Herbst’s team has also identified a relevant mouse model exhibiting the hypomyelination pathology associated with schizophrenia to be used for future research. In addition to the cell and mouse models, the BioMed X neuroscientists have analyzed the RNA expression of different human brain regions in post-mortem samples from schizophrenia patients and controls. Their soon-to-be-published findings reveal that there are differentially expressed genes and pathways in schizophrenia brains, particularly in oligodendrocytes, when compared to control brains, which could have significant implications for designing new therapies, not only for schizophrenia but also for other neurological disorders like major depressive disorder or bipolar disorder, which share a common hypomyelination pathology.

Dr. Christian Tidona, Managing Director & Founder of the BioMed X Institute: “This is already our second successfully completed project with Boehringer Ingelheim in the field of psychiatry. We are looking forward to continuing our successful collaboration with our ongoing research projects in brain sensor development in Heidelberg and in the field of wound healing and fibrosis at our new joint XSeed Labs on the U.S. campus of Boehringer Ingelheim in Ridgefield, CT.”

“Together with partners from across the global neuroscience community, we are constantly exploring new scientific avenues to address the huge unmet need of those living with mental health conditions,” Hugh Marston, Global Head CNS Discovery Research at Boehringer Ingelheim, stated. “The partnership with BioMed X and the fruitful collaboration with Dr. Ercan Herbst’s team has yielded exciting insights that will help us initiate projects to further progress our precision psychiatry approach to transform patients’ lives.”

About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27

SOURCE: BioMed X Institute

AsiaMedic partners with Sunway to establish new diagnostic imaging centre

The planned close to 6,000 sqft facility at Royal Square in Novena is expected to commence operations by November 2024 and will nearly double AsiaMedic’s diagnostic imaging capacity.
AsiaMedic’s continued capacity expansion follows three consecutive years of revenue growth which reached a record high for FY2023.

SGX Catalist-listed AsiaMedic Limited (the Company and together with its subsidiaries, the Group) announced that the Company’s wholly-owned subsidiary, AMC Healthcare Pte. Ltd (AMC), has entered into a shareholders’ agreement with Sunway Equity Holdings Pte. Ltd. (SEH) to set up and operate a new medical diagnostics imaging centre in Novena, Singapore.

Mr Arifin Kwek, Chief Executive Officer of AsiaMedic Limited and Ms Sarena Cheah, Executive Director of Sunway Berhad [L-R]

AMC and SEH will establish AsiaMedic Sunway Pte. Ltd. to operate the new centre in Novena, which will provide a comprehensive range of general imaging as well as sub-specialised fields of radiology imaging such as computed tomography (CT) scans and magnetic resonance imaging (MRI) scans using the latest equipment.

Mr Arifin Kwek, Chief Executive Officer of AsiaMedic Limited, said, “The partnership with Sunway presents an opportunity for expansion of the Group’s diagnostic imaging business into Novena, which is a significant healthcare and medical services hub in Singapore. This will greatly complement the Group’s existing integrated medical centre at Orchard Road and enable us to serve more patients with greater convenience.”

The new diagnostic imaging centre will offer the same cutting-edge imaging services as the Group’s flagship centre at Orchard Road, which significantly expanded its capacity in September 2023 by being the first in Asia Pacific to operate the SIGNA™ Hero 3T MRI scanner. Once completed, the new centre in Novena will nearly double the Group’s diagnostic imaging capacity.

In FY2023, diagnostic imaging and radiology services revenue increased by 72% and contributed nearly 50% of Group revenue. Demand for the Group’s services remained strong across the entire spectrum of healthcare providers with an increase in referrals from clinics and hospitals.

Ms Sarena Cheah, Executive Director of Sunway Berhad, said, “We are confident in the long-term prospects of our partnership as AsiaMedic has a trusted track record and aptitude in providing tailored offerings to its patients. In addition, the new diagnostic imaging centre’s strategic location and close proximity to other healthcare providers will position us as the preferred choice for patients. This partnership will offer strategic benefits to Sunway and enhance our existing healthcare ecosystem.”

SEH is wholly-owned by Sunway City Sdn Bhd which in turn is wholly-owned by Sunway Berhad, one of Southeast Asia’s most prominent conglomerates and one of the leading private healthcare groups in Malaysia.

AsiaMedic continues to invest in the latest technology to enhance the patient experience and maintain its position as a preferred provider of diagnostic imaging radiology services. In March 2024, the Group became the first in Singapore to install the latest Revolution™ Apex Elite CT scanner. The Group will also continue to explore potential opportunities for further expansion and long-term growth.

This press release should be read in conjunction with the announcement uploaded on SGXNet.

For media and analysts’ queries, please contact:
Waterbrooks Consultants
Wayne Koo
T: (65) 9338 8166
E: wayne.koo@waterbrooks.com.sg

About AsiaMedic Limited
AsiaMedic Limited together with its subsidiaries (AsiaMedic or the Group) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to prevent and detect early illnesses to achieve positive experiences and clinical outcomes for patients.

The Group is committed to helping clients through practical and personalised solutions delivered with the highest professional standards of service and expertise in a timely, safe and consistent manner. Conveniently located at Orchard Road, AsiaMedic is a preferred one-stop centre for:

Diagnostic imaging and radiology services
Medical wellness and health screening services
Primary healthcare services
Medical aesthetic services and products

For more information, please visit www.asiamedic.com.sg

Vinmec’s Innovations Spotlighted at Global CSR & ESG Summit 2024

The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam. The event showcased tremarkable strides in corporate social responsibility (CSR) and environmental, social, and governance (ESG) initiatives, and featured some of the most outstanding achievements by enterprises and organizations in this regard.

Vietnam’s Vinmec Healthcare System received platinum awards for Best Community Program, Best Workplace Practices, Empowerment of Women, and Best Country Excellence in Vietnam in the US$1 billion and above market capitalization category.

Founded in 2012 to contribute to sustainable development in the Vietnamese healthcare sector by delivering high-quality medical services, Vinmec stands as a beacon of academic healthcare, dedicated to shaping the global healthcare narrative through innovative research, groundbreaking discoveries, and a steadfast commitment to clinical excellence and value-based care solutions.

In an interview with ACN Newswire, Vinmec CEO Le Thuy Anh discusses the company’s visionary objectives and operational aspirations, and how, amid an era marked by pressing healthcare challenges, the company’s resilience, foresight, and unwavering dedication are helping transcend geographical boundaries by creating a sustainable healthcare ecosystem.

ACN: Can you share with us the vision and mission of Vinmec, particularly its dedication to academic healthcare for people at local and global scales?

Le Thuy Anh: Vinmec’s vision revolves around addressing critical healthcare challenges nationally and globally, especially in light of the transition from communicable to non-communicable diseases and an aging population. Vinmec is pioneering as an agent of change based on a model of academic medicine with three pillars: excellence in clinical programs; innovative research; and medical education. Aligning with this vision, Vinmec’s mission is caring with compassion, professionalism, and wisdom based on the core values of C.A.R.E (Creativity, Accountability, Reliability, Excellence). Based on this, we aim to contribute significantly to sustainable healthcare development by delivering high-quality medical services, focusing on academic healthcare through innovative research and clinical excellence.

ACN: How does Vinmec approach innovation, research, and breakthroughs to achieve clinical excellence?

Le Thuy Anh: Our approach to innovation and research is integral to achieving clinical excellence. We invest significantly in research and technology transfer, operate research institutes like Vinmec Research Institute of Stem Cells and Gene Technology (VRISG) for stem cell therapies, and the Hi-tech Center for groundbreaking trials.

VRISG is a pioneering research institute specializing in stem cell therapies for a range of rare diseases and is also the first to utilize CAR-T cell therapy for leukemia treatment in Vietnam. Vinmec’s Hi-tech Center has achieved significant milestones, including conducting large-scale clinical trials for COVID-19 vaccines, successful international clinical trials on the efficacy of new cancer drugs, and becoming a reference laboratory for renowned medical partners like AstraZeneca.

Our emphasis on cutting-edgeinnovative applications like 3D printing and robotic surgery ensures clinical excellence and value-based solutions for our patients.

ACN: Creativity is highlighted as a core value of Vinmec. Can you provide examples of how the organization fosters continuous innovation to offer patients the best solutions?

Le Thuy Anh: Creativity drives our long-term development and breakthroughs, evident in our research findings turned into clinical trials like Car-T cell therapy for leukemia and stem cell transplantation in the treatment of autism and cerebral palsy, to name a few.

We empower our doctors with modern techniques and equipment through many training and clinical observership programs in the developed countries of medicine. We continuously innovate in workplace practices through initiatives like the Creativity Subcommittee, Kaizen, PDSA, and lean operations fostering a culture of excellence and implementing ideas that enhance quality and customer experience at all levels.

ACN: Accountability is crucial in healthcare. How does Vinmec ensure the highest level of accountability to patients and their families in terms of care ethics, skills, knowledge, and professional standards?

Le Thuy Anh: We ensure accountability through JCI accreditation, rigorous safety programs, and continuous training for our staff. Vinmec is the first and only healthcare system in Vietnam having two hospitals accredited by Joint Commission International (JCI) – the world’s most rigorous standards in hospital quality and patient safety.

Our focus on patient safety, through programs like Daily Safety Huddles where we hold a brief meeting in the morning between specialties, heads of departments, and other stakeholders to discuss clinical issues of patients; and the SpeakupSpeak up for every clinical staff to share and point out the patient’s risks reflects our commitment to the highest professional standards and ethics in delivering healthcare services.

Vinmec’s people play a key role in delivering the highest quality levels of healthcare, so we focus on continuous training and the well-being of the staff. As the first and only private academic healthcare model in Vietnam, excellence through persistent and personalized education is decisive for all Vinmecers, leading to delivering best practices.

ACN: Reliability is emphasized as a core value of Vinmec. How does the organization demonstrate its commitment to being the most reliable healthcare provider to the community?

Le Thuy Anh: Our commitment to reliability is evident through community initiatives, financial support for patients, and our response to healthcare crises like COVID-19.

Throughout 12the 12 years since its establishment, Vinmec has been entirely engaged in building a sustainable community.

Our business goals are always set in parallel with the benefits for the community at large. Thus, Vinmec is the only private healthcare system pursuing the model of a “not-for-profit” and value-based healthcare model in operation in Vietnam.

Vinmec’s contributions to the community are presented through community free health screening for over 15,000 people (in the past 5 years), financial support of VND300 billion annually for patients, medical education, and technology transfer for peer hospital and provincial hospitals.

Last but not least, Vinmec strongly responsed to Vingroup’s fight against COVID-19, making significant contributions in terms of human and material resources.

ACN: Excellence is a fundamental value for Vinmec. Could you discuss the organization’s approach to pursuing the highest service quality and implementing the best healthcare practices?

Le Thuy Anh: Pursuing excellence is at the core of our operations, seen through strategic partnerships, international accreditations, and Centers of Excellence for various disease groups.

Vinmec’s strategic partnerships with industry leaders like Cleveland Clinic and GE Healthcare have facilitated continuous improvement in service quality by leveraging advanced techniques and expertise. Over 12 years, Vinmec has received numerous international awards and accreditations, establishing Centers of Excellence (CoE) in critical areas like Cardiology, Orthopedics, Oncology, and Immunology, recognized globally for their cutting-edgeinnovative technology and specialist teams. Notably, the COE for Cardiology of Vinmec Times City International Hospital and Vinmec Central Park International Hospital were honored by the American College of Cardiology as the first centers of excellence in Asia.

Our focus on optimized treatment efficiency and outstanding service quality, along with continuous learning and improvement, ensures the best value-based solutions for our patients.

ACN: How does Vinmec ensure that compassion, professionalism, and wisdom are integrated into its care delivery model and reflected in the patient’s experience?

Le Thuy Anh: We take our responsibility extremely seriously and are committed to our mission of providing the utmost quality of care for our patients with professionalism, wisdom, and compassion. Our mission transcends the provision of healthcare services. It encompasses a commitment to nurturing a workplace where every member feels valued, respected, and motivated to excel.

At Vinmec, we believe in creating value not only for our patients but also for our people – the heart of our organization. This commitment is reflected profoundly in our workplace practices, where we strive to create an environment that not only fosters growth and recognition, but also integrates the core values of C.A.R.E (Creativity, Accountability, Reliability, Excellence) into every facet of our operations.

Our approach to workplace practices is holistic, focusing on the Total Rewards policies that motivate, develop, and nurture our employees. Holistic care extends through various stages of an employee’s journey, including recruitment, integration, promotion, training, and development. Meanwhile, Vinmec’s Comprehensive Care Program, “Vinmec Health & Wellbeing,” offers a holistic approach to employee wellness, encompassing mental and physical health, career development, and family and social connections. This initiative underscores Vinmec’s commitment to fostering a nurturing and supportive environment for all our staff, ensuring a well-rounded support system.

Our CARE culture forms the foundation of the Vinmec management framework. At Vinmec, we focus on value-based leadership, where our leaders exemplify the CARE principles in their daily actions. Vinmec has established a Cultural Framework with activities promoting the distinctive CARE culture. These activities are implemented deeply within the framework, following a planned timeline and themes for each quarter. The cultural activities have seen widespread and enthusiastic participation from members.

As a result, Vinmec is the first and only healthcare system in Vietnam that received the “Best Place to Work” award in 2023.

ACN: Looking ahead, what are the future plans and goals for Vinmec in terms of furthering its mission of academic healthcare and delivering excellence in patient care?

Le Thuy Anh: Our future plans include expanding our hospital network, treating rare diseases, promoting preventive medicine, and adopting advanced healthcare models. We aim to remain a factor of change and sustainability in Vietnamese medicine, delivering academic healthcare excellence and achieving international standards of care.

Vinmec has steadfastly pursued its vision of becoming Vietnam’s first academic private healthcare system, emphasizing creativity and innovation to address complex medical challenges and promote preventive medicine, patient engagement, and the adoption of P4 medicine (Predictive, Preventive, Personalized, Participatory).

The upcoming opening of two new Vinmec hospitals will expand its network to nine international hospitals nationwide, showcasing its ongoing commitment to excellence and attainment of world-class quality certificates.

About Vinmec

Vinmec is dedicated to academic healthcare for people at local and global scales through innovation research and breakthroughs that lead to clinical excellence and value-based care solutions. For more information visit, https://en.vinmec.com.

Media contact:
Tram Nguyen – Corporate Branding Specialist
v.tramnn17@vinmec.com

Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea

Seoul Office Announced at BIO Korea 2024

Avance Clinical

Meet with the team at BIO Korea

Find out more:

Learn about the GlobalReady modelFor more information about the benefits of running your next study with Avance Clinical contact usRequest a Proposal here

Media Contact:

media@avancecro.com

About Avance Clinical

Frost & Sullivan Awards

Pre-clinical through to mid to late phase

Technology

www.avancecro.com

Lithuanian Biotech Pioneer ‘Nando’ Embarks on Global Expansion With New Management Team and Innovative Production Line

“Nando”, a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its management team and an ambitious expansion of its biotechnological production line. This move is set to position “Nando” not just as a leader in Lithuania but as a formidable player on the international stage.

In a strategic enhancement of its management team, Nando welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations. Gytis Kubilius, with a solid background in management at SEB and Citadele banks; Mindaugas Navickas, previously International Sales Manager at Teltonika Networks; ArÅ«nas Jusas, former General Manager at Timac AGRO; and GiedrÄ— MockienÄ—, who served as HR Manager at UAB Yara, are now integral parts of Nando’s leadership, aiming to spearhead ambitious development projects.

To cater to the surging demand for microbiological alternatives to mineral fertilizers and plant protection products, “Nando” has invested about €3 million in a unique biotechnology line. This investment boosts production volume, enhances productivity, and ensures competitive pricing to meet the escalating market demand. With a technology that is currently patent-pending, “Nando” exports to over 20 countries, including Great Britain, Ukraine, Estonia, Kazakhstan, Latvia, Poland, Romania and beyond.

Justinas Taruška, CEO of “Nando”, stated, “Our main goal is to feature a highly automated biotechnological production line. This will not only elevate the agro-biotechnology sector’s value in Lithuania but also accelerate sustainable and economically viable agricultural technologies across Europe and other continents.” The new production line is renowned for its unique microorganism purification technology, a rarity in the entire Baltic region. It promises an efficient production of stable, high-yield microbiological products in powder form, a technology with limited competition.

The inclusion of new management members, with their extensive international experience, underscores “Nando’s” commitment to employee development and its focus on penetrating foreign markets, including Europe, North and South America, Asian and Africa countries. This strategic move coincides with the launch of the new production line for microbiological products.

Founded in 2007, “Nando” stands at the forefront of the biotech industry, developing and manufacturing microbiological products and chemical additives for agriculture. With one of Northern Europe’s leading R&D centers and partnerships with global research institutions, “Nando” has introduced over 50 innovative products, vital to the agro, livestock. Currently, the company is intensifying its export activities, with operations spanning over 20 countries in Europe, North and South America, Asian and Africa. The “Nando Group” proudly employs more than 50 professionals dedicated to advancing global biotechnology solutions.

Contact Information:
Milda Gauliene
Marketing specialist
milda@nando.lt
+37066475297

SOURCE: Nando

View the original press release on newswire.com.

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.

BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.

Independent of tumor indication, the general immunogenicity of a tumor is positively correlated with a better prognosis and a more robust response to immune checkpoint blockade. The current paradigm envisions tumor mutations as one of the sources of immunogenic neoantigens, which are expressed and presented on the surface of the tumor cells and recognized by the immune system to mount an effective anti-tumor response. The main objective of this research group is to identify how the DNA damage response (DDR) can be harnessed to increase the immunogenicity of tumor cells. The final goal is to design novel therapeutic approaches that promote a favorable tumor microenvironment for immunotherapies.

Dr. Semih Akincilar, the scientist leading this project, explains: “Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment.”

The BioMed X Institute and Merck have been collaborating since 2013, partnering on both oncology and immunology research projects, with the end goal of developing new therapies for cancer and autoimmune diseases. “With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology,” said Christian Tidona, Founder and Managing Director of the BioMed X Institute. Further details about this project can be found on the BioMed X Institute website (www.bio.mx).

Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

SOURCE: BioMed X Institute

View the original press release on newswire.com.

CanSinoBIO CSO Shares the Latest Results of the Company’s Globally Innovative Pneumococcal Vaccine

On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong’an New Area of Hebei Province. Dr. Tao Zhu, Chief Scientific Officer (CSO) of CanSino Biologics Inc. (CanSinoBIO), was invited to give a presentation at the conference.

Dr. Zhu introduced the latest progress and breakthrough made in the development of pneumococcal vaccines both in China and abroad, focusing on sharing the latest results from the clinical trials of the company’s globally innovative protein-based pneumococcal vaccine (PBPV). He said that the PBPV is unique in terms of its broader coverage, serotype-independent and simpler production process while triggering good immune memories, and is expected to further improve the protection against pneumococcal diseases. Positive results have been obtained from Phase I clinical trials of the PBPV.

The results of Phase Ia and Phase Ib clinical trials showed that PBPV has a good safety profile in adults aged over 18 years old (including the elderly over 50 years old). A single dose of vaccination was found induce significant binding antibody and functional bactericidal antibody responses against cross-family/clade of Streptococcus pneumoniae, which further demonstrated the broad spectrum and potential public health value of this vaccine candidate.

When talking about the platforms for the development of innovative vaccines as well as the development of multi-valent vaccines and conjugate vaccines, Dr. Zhu said that CanSinoBIO has built five such platforms and a highly competitive pipeline, including multiple vaccine candidates targeting 10-plus indications like meningitis, pneumonia, DPT, shingles, and tuberculosis.

Dr Zhu emphasized the company has developed a comprehensive strategy to combat pneumonia-related illness. He said that CanSinoBIO has laid a solid foundation for the subsequent development of those candidates and their launch in overseas markets with its unique vectors and animal component free media (ACFM). The company is committed to developing pneumococcal vaccines, especially higher-valency serotype vaccines to improve the effectiveness of vaccines.

In the future, CanSinoBIO will continue to drive the innovation and development of vaccines with a global vision by enhancing collaboration with international partners, and contribute more to public health around the world.

About PBPV

PBPV is a globally innovative pneumococcal vaccine candidate. Unlike the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 13-valent pneumococcal conjugate vaccine (PCV13), PBPV is not serotype-dependent. It mainly adopts antigens that are based on the pneumococcal surface protein A or PspA, which is a highly-conserved protein expressed by virtually all pneumococci. Compared with currently marketed PPV23 and PCV13, PBPV has broader coverage (at least 98% coverage of pneumococcal strains), which can effectively prevent serotype replacement. Meanwhile, this product has a simpler production process than polysaccharide vaccines and conjugate vaccines, facilitating scale-up and quality control.

About CanSinoBIO

Incorporated in 2009, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) commits to providing high-quality, innovative, and affordable vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a rich portfolio of a pipeline products preventing more than 10 diseases, including the Aisa’s first and only vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia® approved in over 10 countries and granted EUL by the WHO, the Asia’s first Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia® and the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia® approved by NMPA in China. The world’s first inhaled COVID-19 vaccine Convidecia Air® has been approved as a booster dose in China, Morocco, and Indonesia. Additional information can be found online at www.cansinotech.com.

New Contaminants, Food Testing & More: analytica Convention 2024 Focuses on Vietnam’s Laboratory Needs

In anticipation of the biennial analytica Vietnam Exhibition scheduled for 2025 in Ho Chi Minh City, the analytica Convention 2024 emerges to bridge the gap year, offering an alternative platform for industry stakeholders. Hosted by analytica Vietnam, this event will take place on May 16th at the Melia Hotel Hanoi, promising a comprehensive exploration of the latest advancements, trends, and challenges shaping the analytical and laboratory technology sector.

Supported by the Key Laboratory of Analytical Technology for Environmental Quality and Food Safety Control (KLATEFOS), VNU, and VNU Key Laboratory of Geo-Environment and Climate Change Response, the one-day convention comprises of a full-day conference program featuring three distinct streams focusing on the “Emerging Contaminants in Food, Pharma, and Environment”, alongside engaging tabletop presentations by industry leading exhibitors.

With over 20 sponsors expected to gather, a diverse array of more than 30 conference sessions, and an audience exceeding 400 delegates, the event promises an immersive and enriching experience for all attendees.

The convention will commence with opening speeches from the Minister of Science and Technology in Vietnam, followed by Daniel Shi, the Project Director of analytica Vietnam from the event organizer, MMI Asia, Pte Ltd, a subsidiary of Messe München GMBH (MMG). The conference programme boasts an extensive lineup of keynote presentation and panel discussions offering attendees invaluable insights and networking opportunities. Renowned speakers from academia and the industry will share their expertise on a wide array of topics, including pivotal trends and strategies that shapes the spheres of Food, Pharma, and Environment. Attendees can expect thought-provoking discussions on a wide range of topics, including:

– Emerging persistent organic pollutants and their impact on environmental chemistry (Prof. Dr. Pham Hung Viet): Professor Viet will shed light on newly discovered pollutants and the challenges they pose, offering valuable insights and solutions for environmental scientists and chemists.

– The evolving role of food testing in the coming decades (Dr. Nguyen Hung Long): Dr. Long will explore the changing landscape of food safety and quality control, outlining the crucial role food testing will play in the future.

– Utilizing UV spectroscopy with signal transformation for multicomponent dosage form analysis (Assoc. Prof. Vu Dang Hoang): Associate Professor Hoang will delve into a novel analytical technique, showcasing its potential to revolutionize the analysis of complex pharmaceutical formulations.

A highlight of the analytica Convention 2024 will be the tabletop exhibition, featuring leading companies such as ITS Vietnam, DKSH Vietnam, HTI Scientific, Anton Paar Vietnam, LGC, IKA Vietnam, Merck Vietnam, Việt Anh JSC, Kimteco Co.,ltd, ACI Sciences, LMS Technologies Vietnam, Mettler Toledo, Navis, and LabVietConnect, showcasing their latest products and solutions. Attendees will have the unique opportunity to explore cutting-edge instrumentation, software platforms, and laboratory equipment, engaging directly with industry representatives to address their specific needs and requirements.

“We are thrilled to host the analytica Convention 2024 in Vietnam, providing a stage for the industry’s leading players to gather and share critical topics, trends, and strategies in analytical sciences,” said Mr. Michael Wilton, CEO & Managing Director of MMI Asia. “This convention serves as a catalyst for driving innovation, fostering collaboration, and advancing the industry as a whole. We look forward to welcoming participants from across Vietnam and beyond to this exciting event.”

Registration for the analytica Convention 2024 is now open. For more information and to register, please visit www.analyticavietnam.com/analytica-convention-2024. Additionally, booth applications for the highly anticipated analytica Vietnam 2025 are now open. Sign up now to take full advantage of the Early Bird Rate, available until May 30th, 2024, with limited spaces available.

About analytica Vietnam

analytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies, exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from April 2 to 4, 2025 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.

About analytica worldwide

Messe München is the world’s leading trade fair organizer for laboratory technology, analysis and biotechnology. The international network of exhibitions includes analytica, analytica China, analytica Anacon India & India Lab Expo, analytica Vietnam and analytica Lab Africa. Additional information about these exhibitions and their programs of events is available at www.analytica.de.

About MMI Asia Pte Ltd

MMI Asia is a full subsidiary of Messe München GMBH (MMG) established in 1992 and one of the world largest and leading exhibition organizers. MMI Asia was set up as the regional headquarter and a wholly-owned subsidiary of MMG to promote global trade expansion by facilitating participation of Asian exhibitors in Messe München fairs worldwide. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations.

About Messe München GmbH

Messe München GmbH is one of the world’s leading trade fair organizers with more than 50 trade fairs for capital goods, consumer goods, and new technologies. Every year, Messe München organizes more than 200 events in Munich, Germany, and abroad, attracting over 30,000 exhibitors and 2 million visitors. The company’s mission is to create innovative, sustainable, and profitable platforms for its customers to do business and connect with their target markets.

Contact:
MMI Asia Pte. Ltd.
Joey Ng
Marketing Executive
+65 9734 7946)
joey@mmiasia.com.sg

Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25

Avance Clinical, the award-winning North American and Australian market-leading CRO for biotechs, will attend World Orphan Drug Conference in Boston (April 23-25, 2024) to share their rare diseases drug development expertise with biotechs (booth #730).

Avance Clinical CEO, Yvonne Lungershausen said that Avance Clinical is dedicated to advancing research and ensuring faster access to therapies that can make a significant difference in patients’ lives.

“Avance Clinical has deep therapeutic knowledge of this area, completing over 50 trials in rare and orphan diseases globally in the last five years, including Fragile X Syndrome, Duchenne Muscular Dystrophy, Rett Syndrome and Erythropoietic Protoporphyria,” she said.

Central to the company’s success in this sector is collaboration with disease-specific advocacy groups, patient registries, and tailored recruitment strategies, to enhance patient enrolment and retention.

Lungershausen said, “We have an extensive understanding of the unique challenges in managing small patient populations. Our patient-centric approach places patients at the heart of our operations, ensuring optimal care through the selection of experienced sites and clinics.

“Avance Clinical engages with clients early in the planning process to tailor trial designs to accommodate the unique needs and challenges faced by patients with rare diseases, ultimately improving patient access to critical medicines,” she said.

Avance Clinical is adept at crafting adaptive, patient-focused protocols that adhere to regulatory standards. The company’s innovative approach to study design, combined with over 26 years of experience in delivering FDA and EMA-quality data, positions Avance Clinical as a CRO capable of navigating the complexities of the regulatory landscape efficiently.

Lungershausen describes Avance Clinical as a mid-sized, agile, and responsive CRO with a proven track record of swiftly advancing high-quality clinical programs. “This makes us an ideal CRO partner for rare disease-focussed biotechs,” she said.

“Avance Clinical is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III,” she said.

“This is our GlobalReady program and we have more than 90 biotech clients leveraging this unique, streamlined multi-region process. With a globalized strategy, we ensure efficiency every step of the way,” she said.

“Biotechs are looking for a partner that can seamlessly help transition rapidly with high-quality data that is readily accepted by the FDA and other regulatory agencies. Our in-house global regulatory affairs team assists biotechs to navigate regulatory complexities with confidence and support our clients with FDA, EMA and TGA submissions,” she said.

“In addition, our GlobalReady Site Partnership Network of over 1,250 highly qualified sites across the United States ensures maximum efficiency and effectiveness in our biotech’s clinical trials, particularly in rare and orphan indications,” she said.

New analysis by market research leader Frost & Sullivan shows one of the major challenges for biotechs was finding the right biotech aligned CRO partner.

“More than 60% of US biotechs experience delays seeking the right CRO partner to accelerate their drug development programs,” Lungershausen said. (See report here).

The comprehensive report underscores the increasing biotech preference to collaborate with the right sized CROs that can accommodate the fast-paced nature of biotech demands.

Executive Vice President, North America Operations, John Mann, will attend the conference in Boston alongside Avance’s team of clinical trial experts, including Senior Vice President, Scientific and Regulatory Affairs Kevin Leach and Director of Business Development Clint Henry.

Visit Booth #730 to discuss your upcoming clinical trial, and find out more about the Avance Clinical Advantage, supporting biotechs globally in their clinical development programs.

Book a meeting with the team here

Find out more:

Learn about the GlobalReady model here https://www.avancecro.com/avance-clinical-north-america-operations/
For more information about the benefits of running your next study with Avance Clinical contact us
Visit Booth #730 to discuss your drug development program at the World Orphan Drug Congress in Boston, April 23- 25

Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson

About Avance Clinical
Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right from pre-clinical consultancy through to Phase III clinical services leveraging global reach, supported by significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.

www.avancecro.com

DC Healthcare Rides the Wave of Success with New Openings at Publika and Bukit Indah

DC Healthcare Holdings Berhad (DC Healthcare or the Group), an aesthetic medical services provider specialising in the provision of non-invasive and minimally invasive procedures, is pleased to announce the opening of one Dr. Chong Clinic and one DC Body in KL Publika Shopping Gallery as well as one DC Body Johor Bahru Bukit Indah following the successful launch of multiple Dr. Chong Clinics and DC Body outlets across Malaysia. These additions aim to enhance the availability of DC Healthcare’s top-quality wellness and aesthetic services.

Dr Chong Clinic – KL Publika Shopping Gallery continues the Group’s offering of premier aesthetic services, building on the reputation of excellence that DC Healthcare has established. Meanwhile, DC Body – KL Publika Shopping Gallery and Johor Bahru Bukit Indah represent an innovative leap for DC Healthcare, extending the Group’s offerings into specialised weight management, personalised nutrition counselling and body contouring.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare said, “The positive feedback from our customers from the recent outlets openings of Dr Chong Clinic and DC Body in Ipoh, Johor, Penang and Selangor has inspired us to continue growing. Our new facilities at Publika and Bukit Indah reinforce our commitment to meet the demand for professional wellness and beauty services. We look forward to serving more customers in these new locations.”

He added, “The selection of Publika aligns with the Group’s strategy to integrate into areas that support the lifestyle preferences of our clients. Both new establishments are designed to meet the high standards of care and professionalism expected from DC Healthcare.”

In 2024, DC Healthcare has expanded its reach by opening four Dr. Chong Clinics located in Taman Molek (Johor Bahru), Bandar Seri Botani (Ipoh), Auto City (Pulau Pinang), and Publika (Kuala Lumpur), as well as four DC Body outlets in USJ Taipan (Selangor), Auto City (Pulau Pinang), Publika (Kuala Lumpur), and Bukit Indah (Johor Bahru). With these latest additions, DC Healthcare now operates a total of 17 medical aesthetic clinics and 4 DC Body outlets nationwide, significantly enhancing the accessibility and availability of its premium wellness and aesthetic services to a broader audience.